Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2-Positive Breast Carcinoma”

961 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 961 results

Testing effectiveness (Phase 2)Ended earlyNCT00138125
What this trial is testing

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 2
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Study completedNCT03112590
What this trial is testing

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, MaleBreast Cancer Female+1 more
H. Lee Moffitt Cancer Center and Research Institute 51
Not applicableEnrolling By InvitationNCT06821490
What this trial is testing

Validation of TAD in HER-2 with More Than 2 Lymph Nodes

Who this might be right for
Breast Carcinoma Metastatic in Lymph NodeHER2 Positive Breast Carcinoma
Fundación para la Investigación del Hospital Clínico de Valencia 21
Testing effectiveness (Phase 2)Ended earlyNCT03241810
What this trial is testing

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Elevation Oncology 22
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Not applicableStudy completedNCT04756921
What this trial is testing

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Who this might be right for
HER2-positive Breast Cancer
Biyun Wang, MD 30
Not applicableStudy completedNCT05458401
What this trial is testing

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 256
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Ended earlyNCT03429101
What this trial is testing

Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Post-approval studies (Phase 4)UnknownNCT05131841
What this trial is testing

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742
What this trial is testing

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 245
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT00191373
What this trial is testing

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Who this might be right for
Breast NeoplasmsCancer of the BreastBreast Cancer
Eli Lilly and Company 66
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Post-approval studies (Phase 4)Looking for participantsNCT06641544
What this trial is testing

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Next Page